Chromadex Corp (OQ:CDXC)

Business Focus: Biotechnology & Medical Research

Mar 26, 2024 08:32 am ET
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen® product portfolio is now third-party verified through the
Mar 06, 2024 04:04 pm ET
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results.
Feb 21, 2024 08:32 am ET
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The financial results will be reported in a press release after the cl
Feb 05, 2024 08:32 am ET
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, February 12, 2024, at 11:00 AM PST. ChromaDex
Jan 26, 2024 04:08 pm ET
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners 2024 Investor Select Conference.
Dec 20, 2023 09:04 am ET
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to announce its inaugural initiative to support the US Military.
Dec 12, 2023 09:30 am ET
Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+
Qualia NAD+, Featuring ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen, Well Positioned To Become Category Leader In NAD+ Supplementation.
Nov 30, 2023 08:34 am ET
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With M
ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson’s disease (PD). This study was part of the
Nov 15, 2023 08:32 am ET
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement
ChromaDex Corp. (NASDAQ:CDXC), one of the global authorities on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results from a phase II clinical study published in the peer-reviewed journal,
Nov 09, 2023 08:32 am ET
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
ChromaDex Corporation (NASDAQ: CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, November 14, 2023, at 2:00 PM EDT. ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend these live events.
Nov 08, 2023 04:02 pm ET
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
ChromaDex Corp. (NASDAQ: CDXC) today announced financial results for the third quarter of 2023.
Nov 01, 2023 08:34 am ET
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to
ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, launches its clinical strength
Oct 31, 2023 08:34 am ET
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 8, 2023 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2023. The financial results will be reported in a press release after the
Oct 26, 2023 08:32 am ET
ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, and
Oct 02, 2023 08:32 am ET
A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and
ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, shares results from a newly published clinical study, as reported in the peer-reviewed journal
Aug 24, 2023 08:32 am ET
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Ade
ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, shares findings from a preclinical study, as reported in the peer-reviewed journal International Journal of Molecular Sciences by a team of scientists led by Dr.
Aug 09, 2023 04:02 pm ET
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2023.
Aug 08, 2023 08:34 am ET
ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announces the appointment of the world’s number one online destination for health and wellness, iHerb, as the newest retail partner to distribute Tru Niagen globally. iHerb is on a mission to make health and wellness accessible to all offering the best brands in the industry and has established a strong international presence, with nearly 90% of sales generated outside of the United States. iHerb has a global audience larger than Vitacost, VitaminShoppe, and GNC combined, proudly totaling 10 million active c
Aug 07, 2023 08:32 am ET
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series
ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, August 14, 2023, at 12:00 p.m. ET (9:00 a.m. PT) and Wednesday, August 16, 2023 at 2:00 p.m. ET (11:00 a.m. PT). ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend these live events.
Aug 02, 2023 08:02 am ET
ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, August 9, 2023 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended on June 30, 2023. The financial results will be reported in a press release after the close of regular s
Jul 18, 2023 08:32 am ET
Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promisin
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+), announced promising findings from two independent clinical study abstracts originally presented this past April at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting and recently published in the peer-reviewed ARVO journal, Investigative Ophthalmology & Visual Science, by a team of scientists led by Dr. Christopher Leung from the Department of Ophthalmology at the School of Clinical Medicine, HKUMed, Hong Kong, and Dr. David F Garway-Heath, Professor of Oph
Jun 16, 2023 08:32 am ET
ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Adv
On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority on nicotinamide adenine dinucleotide (NAD+) research and healthy aging, celebrated the 10th anniversary of its award-winning
May 30, 2023 08:34 am ET
ChromaDex to Participate in the LD Micro Invitational XIII
ChromaDex Corp. (NASDAQ:CDXC) today announced that it will be participating at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private 1:1 meetings.
May 11, 2023 08:34 am ET
ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2023 Investor Conference.
May 10, 2023 04:02 pm ET
ChromaDex Corporation Reports First Quarter 2023 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2023.
May 02, 2023 08:32 am ET
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2023. The financial results will be reported in a press release after the close of
Mar 08, 2023 04:02 pm ET
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results
ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2022 financial results.
Mar 06, 2023 08:34 am ET
ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced that senior management will participate at the 35th annual
Feb 27, 2023 08:32 am ET
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year, which ended December 31, 2022. The financial results will be reported in a press rele
Feb 22, 2023 08:34 am ET
ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, holds an exclusive license from Queen’s University Belfast for methods of making nicotinamide riboside (NR) and related derivatives, some of the most efficient nicotinamide adenine dinucleotide (NAD+) precursors, and today announced it expanded this patent family with newly granted U.S. Patent
Feb 21, 2023 08:32 am ET
A Letter from the ChromaDex Chief Executive Officer
The following is issued on behalf of ChromaDex (NASDAQ: CDXC).
Jan 31, 2023 08:32 am ET
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind clinical study, as reported in the peer-reviewed journal Translational Neurodegeneration by a team of scientists led
Jan 17, 2023 08:28 am ET
ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind five-month-long clinical study, as reported in the peer-reviewed journal Science Advances by a team of scientists led by Dr. Eija Pirinen (University of Helsinki and Universi
Jan 12, 2023 08:34 am ET
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc. to its Scientific Advisory Board (SAB). Dr. Bohr is one of the world’s most published researchers on aging and neurodegenerative disease with over 590 journal publications. For the past 30 years, Dr. Bohr served as Chief of the Laboratory of Molecular Genetics at the National Institute on Aging, which is part of the National Institute of Health (NIH).
Jan 05, 2023 08:33 am ET
ChromaDex Named Brianna Gerber Chief Financial Officer
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it has appointed Brianna Gerber to the role of Chief Financial Officer, effective January 1, 2023. Gerber served as Senior Vice President, Finance / Interim Chief Financial Officer of ChromaDex since August 11, 2022, and prior to that was the Vice President of Finance and Investor Relations of ChromaDex since September 17, 2018.
Dec 27, 2022 08:30 am ET
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Po
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising new findings based on a previously published clinical trial of company’s proprietary Niagen® ingredient (patented nicotinamide riboside or NR), which was supported by the ChromaDex External Research Program (CERP™). The new study, published in the peer-reviewed journal
Nov 11, 2022 08:12 am ET
ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that on November 4, 2022, the U.S. FDA declared nicotinamide mononucleotide (NMN) may no longer be sold or marketed as a dietary supplement in the United States since it was first investigated as a drug.
Nov 02, 2022 04:02 pm ET
ChromaDex Corporation Reports Third Quarter 2022 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2022.
Oct 26, 2022 08:35 am ET
ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 2, 2022 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2022. The financial results will be reported in a press release after the
Oct 24, 2022 08:32 am ET
ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that its consumer nicotinamide adenine dinucleotide (NAD+) boosting supplement,
Oct 11, 2022 07:32 am ET
ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment
ChromaDex Corp. (NASDAQ:CDXC) (“the Company” or “ChromaDex”) a global bioscience company dedicated to healthy aging, announced today a new long term commercial license and supply agreement with Nestlé Health Science, a global leader in science-based nutritional health solutions. The new agreement expands the previous supply agreement executed in 201
Oct 04, 2022 06:32 am ET
ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction
ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a clinical study, as reported in the peer-reviewed journal Journal of the American College of Cardiology (JACC): Basic to Translational Science by a tea
Oct 03, 2022 07:30 am ET
ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock
ChromaDex Corp. (NASDAQ:CDXC) (the “Company”), a global bioscience company dedicated to healthy aging, today announced that it has established a joint venture through its wholly owned subsidiary ChromaDex Asia Pacific Ventures Limited (the “JV” or “ChromaDex Asia”). The JV collectively consists of the Company and Hong Kong Taikuk (China) Group Limit
Sep 19, 2022 06:05 pm ET
Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)
ChromaDex Corp. (NASDAQ:CDXC) today announced that Sinopharm Xingsha will debut Tru Niagen® at the major mainland China trade show, China International Natural Health & Nutrition Expo (NHNE), which kicks off Tuesday, September 20, in Shanghai. NHNE is Asia’s largest expo on natural health and nutrition
Sep 01, 2022 06:32 am ET
ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil
ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen® and
Aug 24, 2022 09:00 am ET
Ayana Bio Announces Appointment of Frank Jaksch as Chief Executive Officer
Health and wellness industry veteran will lead the company to scale sustainable bioactives using plant cell technology instead of agriculture                                                     
Aug 15, 2022 06:34 am ET
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced the U.S. Patent & Trademark Office’s Patent Trial and Appeal Board’s (“PTAB”) decision to reject Thorne Research, Inc. attempt to invalidate U.S. Patent No. 8,197,807 (“the 807 patent”). ChromaDex holds an exclusive license to the 807 patent for compositions including nicotinamide riboside (NR) from the Trustees of Dartmouth College. The decision, if upheld upon appeal, precludes Thorne Research, Inc. from raising these arguments, or any other arguments they could have reasonably rai
Aug 10, 2022 04:02 pm ET
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2022.
Aug 02, 2022 06:32 am ET
ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. August 10, 2022 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2022. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
Jul 07, 2022 06:32 am ET
ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)
ChromaDex Corp. (NASDAQ:CDXC) today announced that it will host a key opinion leader (KOL) webinar on the transforming benefits of nicotinamide riboside (NR) on Wednesday, July 20, 2022 at 11:00 am Eastern Time.
Jun 15, 2022 06:34 am ET
ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)
ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and two ChromaDex External Research Program (CERP™) investigators, will be presenting at several key scientific conferences including the American Society for Nutrition’s (ASN) Nutrition 2022, the International Society of Sports Nutrition (ISSN) annual meeting, and Federation of American Societies for Experimental Biology (FASEB), The NAD+ Metabolism and Signaling Conference.
Jun 10, 2022 09:31 am ET
Thinking about buying stock in Nio, Redbox Entertainment, Agora, Chromadex, or Beyondspring?
NEW YORK, June 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, RDBX, API, CDXC, and BYSI.
Jun 10, 2022 06:32 am ET
ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced a signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of
Jun 07, 2022 01:33 pm ET
ChromaDex to Present at the Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference
ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference.
Jun 02, 2022 06:34 am ET
ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea
ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with Juvenis to conduct cross-border sales of Tru Niagen® in South Korea. Juvenis is a Korean healthcare marketing company with a focus on the cosmetic and dietary supplement industries. With strong partnerships in a dynamic and trend-setting Korean market, Juvenis emphasizes products with differentiated science and proven benefits.
Jun 01, 2022 06:32 am ET
ChromaDex to Present at the LD Micro Invitational
ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the 12th annual Invitational. This three-day investor conference is expected to feature around 200+ companies.
May 19, 2022 04:34 pm ET
ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced it has entered into an agreement (the “JV Agreement”) to establish a joint venture through its wholly owned subsidiary ChromaDex Asia Limited (the “JV” or “ChromaDex Asia”). Upon establishment of the JV, membership of ChromaDex Asia will collectively consist of the Company; Crystal Lake Developments Limited; Pioneer Idea Holdings Limited; and Hong Kong Taikuk (China) Group Limited. ChromaDex Asia is expected to assume the distribution agreement noted in a
May 17, 2022 06:34 am ET
ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®
ChromaDex Corp. (NASDAQ:CDXC) announced today that NutraIngredients, a leading news source for the nutrition industry, recently honored the
May 12, 2022 04:03 pm ET
ChromaDex Corporation Reports First Quarter 2022 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2022.
Apr 29, 2022 06:32 am ET
ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs. May 12, 2022 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2022. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
Apr 22, 2022 06:34 am ET
ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors
ChromaDex Corp. (NASDAQ: CDXC) today announced that it has appointed two new members to its Board of Directors: Kristin Patrick, Executive Vice President and Chief Marketing Officer of Claire's Inc., and Ann Cohen, Executive Vice President and Chief Financial Officer of The Institute of Internal Auditors (The IIA).
Apr 14, 2022 06:32 am ET
ChromaDex External Research Program (CERP™) Celebrates Over 250 Research Agreements With 235+ Researchers Around the World
ChromaDex Corp. (NASDAQ:CDXC) today celebrates over 250 material transfer agreements (MTAs) through the ChromaDex External Research Program (CERP™), featuring ChromaDex’s flagship ingredient Niagen® (patented nicotinamide riboside, or NR) and other proprietary ingredients. Over 235 independent scientists, doctors, and invest
Apr 06, 2022 06:32 am ET
ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio
ChromaDex Corp. (NASDAQ:CDXC) today announced the company’s latest product innovation with the U.S. launch of Tru Niagen® Immune, a first-of-its-kind combination of ChromaDex’s proprietary NAD-boosting ingredient Niagen® (patented nicotinamide riboside or NR), high-quality and proven immune-boos
Mar 16, 2022 06:31 am ET
ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations
ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted an additional continuation patent, U.S. Patent No. 11,274,117, adding to its g
Mar 09, 2022 04:02 pm ET
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results
ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2021 financial results.
Mar 02, 2022 06:33 am ET
ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinson’s Disease (PD)
ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study, as reported in the peer-reviewed journal Cell Metabolism by a team of scientists led by Prof. Charalampos Tzoulis, Haukeland University Hospital and University of Bergen, in Norway. The cli
Feb 22, 2022 06:34 am ET
ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. March 9, 2022 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended December 31, 2021. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
Feb 09, 2022 06:34 am ET
ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside
ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted a continuation patent, adding to its global patent portfolio surrounding nicotinamide riboside (NR) and other nicotinamide adenine dinucleotide (NAD) precursors. ChromaDex currently holds a robust patent portfolio of over 40 granted or licensed patents relating to Niagen® (patented NR) and other precursors to NAD, a molecule at the forefront of the healthy aging and cellular health categories. Niagen® is the sole active ingredient in ChromaDex’s flagship product, Tru Niagen®.
Jan 31, 2022 06:32 am ET
ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients
ChromaDex Corp. (NASDAQ:CDXC) celebrates the ChromaDex External Research Program’s (CERP™) 100th published peer-reviewed study on the company’s flagship ingredient Niagen® (patented nicotinamide riboside, or “NR”) and other proprietary ingredients. CERP, the program pioneering NR research, is the first-of-its-kind to reach s
Jan 25, 2022 06:32 am ET
ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation
ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen® (patented nicotinamide riboside, or “NR”) ingredient with promising, peer-reviewed findings reported in the Journal of Clinical Investigation. The study investigated the anti-inflammatory effects of Chro
Jan 20, 2022 06:33 am ET
ChromaDex and Designs for Health Partner for New Product Development on Niagen®
ChromaDex Corp. (NASDAQ:CDXC) today announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs). ChromaDex’s proprietary healthy aging ingredient Niagen®, the world’s first and only FDA-safety reviewed and patented form of nicotinamide riboside, will be added to multi-ingredient Designs for Health formulas. The new products will be available exclusively through the company’s extensive healthcare practitioner (HCP) network.
Nov 03, 2021 04:02 pm ET
ChromaDex Corporation Reports Third Quarter 2021 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2021.
Oct 18, 2021 06:34 am ET
ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)
ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movement Disorders, conducted by Michèl A.A.P. Willemsen MD, PhD of Radboud University Medical Center. The study investigated ChromaDex’s pr
Oct 13, 2021 06:33 am ET
ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wednesday, Nov. 3, 2021 at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sep. 30, 2021. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
Oct 01, 2021 06:33 am ET
ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for Growth
ChromaDex Corp. (NASDAQ:CDXC) today announced that a jury in the United States District Court for the Central District of California found that Elysium Health, Inc. (“Elysium”) breached its contract with ChromaDex by failing to pay for product it ordered and received in 2016. Based on the jury’s verdict, Elysium and Mark Morris will be required to pay ChromaDex approximately $2.25 to $2.50 million in damages and estimated interest.
Sep 29, 2021 06:37 am ET
ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China
ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. (“Sinopharm Xingsha”) to conduct cross-border sales of Tru Niagen® in mainland China. Sinopharm Xingsha is a subsidiary of Sinopharm Group, with businesses including pharmaceutical manufacturing, marketing and distribution of drugs, and food supplements and healthcare products. It is the main platform of Sinopharm Group for food supplements and healthcare products. Sinopharm Group is a large healthcare group directly under the State-owned Assets Supervision and Administration
Sep 20, 2021 06:33 am ET
ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)
ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen® (patented nicotinamide riboside, or “NR”) in various health outcomes. Through the industry-leading ChromaDex External Research Program (CERP™
Aug 03, 2021 04:02 pm ET
ChromaDex Corporation Reports Second Quarter 2021 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2021.
Jul 20, 2021 06:33 am ET
ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., August 3, 2021 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2021. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
Jun 16, 2021 06:33 am ET
ChromaDex Shares Research Findings from the ChromaDex External Research Program (CERP™)
ChromaDex Corp. (NASDAQ:CDXC) today announced the results of four recently published preclinical studies, highlighting new findings for its patented nicotinamide riboside (NR) healthy aging nutrient.
Jun 07, 2021 06:33 am ET
ChromaDex and Walmart Launch Tru Niagen® in 3,800 Walmart Stores Across the United States
ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of its flagship consumer product Tru Niagen® in Walmart, available in 3,800 stores across the United States. Walmart is the first major U.S. retailer to bring this well-studied healthy aging nutrient to stores.
May 06, 2021 04:02 pm ET
ChromaDex Corporation Reports First Quarter 2021 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2021 financial results.
May 04, 2021 06:33 am ET
ChromaDex and Ro Partner for New Product Development
ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered into a strategic supply agreement for Niagen® with Ro, a healthcare-technology company. The agreement provides Ro with rights to ChromaDex’s patented nicotinamide riboside ingredient Niagen®, the sole active ingredient in Tru Niagen®, for specially formulated Roman products.
May 03, 2021 06:33 am ET
ChromaDex to Present at Benzinga’s Global Small Cap Conference on May 13, 2021
ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the Benzinga Small Cap Conference on Thursday, May 13, 2021 at 11:30am ET (8:30am PT). ChromaDex CEO, Rob Fried, will also be presenting on a panel in the Transformative Healthcare track, entitled “Investing in Longevity Science: The New Drugs & Therapies Designed to Prolong Your Lifespan.” The panel is scheduled for Thursday, May 13, 2021 at 1:20pm ET.
Apr 29, 2021 06:33 am ET
ChromaDex to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 6, 2021 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2021. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
Apr 28, 2021 06:33 am ET
ChromaDex and Health & Happiness (H&H) Group Announce Supply Agreement for Niagen®
ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a strategic supply agreement with Health & Happiness (H&H) Group, a global leader in premium health, human and pet nutrition and personal care brands. The agreement provides H&H Group with rights to ChromaDex’s patented nicotinamide riboside ingredient Niagen®, the sole active ingredient in Tru Niagen®, for exclusively formulated Swisse® products. Tru Niagen® is an industry-leading, award-winning dietary supplement that helps users Age Better® by safely and effectively increasing NAD+ (nicotinamide adenine dinucleotide) l
Apr 19, 2021 06:33 am ET
ChromaDex Appoints Fadi Karam as Chief Marketing Officer
ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Fadi Karam as Chief Marketing Officer.
Mar 31, 2021 06:33 am ET
ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency
ChromaDex Corp. (NASDAQ: CDXC) today announced a new research initiative with the Citrin Foundation of Singapore to study the effects of Niagen® nicotinamide riboside (NR) and citrin deficiency, a rare genetic condition. In collaboration with the ChromaDex External Research Program (CERP™) and leading research institutions, the Citrin Foundation will fund a series of preclinical and clinical studies to explore the potential impact of increased NAD+ levels on patients with citrin deficiency. The first study, led by Prof. Paul M. Yen and other scientists at Duke-NUS Medical School in
Mar 24, 2021 06:33 am ET
ChromaDex to Present at the Lytham Partners Spring 2021 Investor Conference
ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Lytham Partners Spring 2021 Investor Conference.
Mar 18, 2021 06:33 am ET
ChromaDex to Present at the Zooming with LD Virtual Investor Conference
ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Zooming with LD investor conference.
Mar 10, 2021 04:02 pm ET
ChromaDex Corporation Reports 2020 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today reported fourth quarter and full year 2020 financial results.
Mar 10, 2021 06:34 am ET
ChromaDex Announces Retail Distribution of Tru Niagen® in Walmart Stores Across the United States
ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product and industry-leading NAD+ booster Tru Niagen® will be available in 3,000 Walmart retail stores across the United States beginning June 2021. ChromaDex will introduce Tru Niagen® in two packaging options for Walmart customers, which will have distinct serving sizes and price points. In addition to in-store availability, these two options will be available online with same-day delivery and in-store pickup options for select locations.
Mar 09, 2021 06:32 am ET
ChromaDex to Present at Oppenheimer 31st Annual Healthcare Conference
ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 3:50pm ET (12:50pm PT).
Mar 08, 2021 06:31 am ET
ChromaDex Appoints Preventative Medicine Specialist Dr. David L. Katz to its Scientific Advisory Board
ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed David L. Katz, MD, MPH, FACPM, FACP, FACLM - CEO of Diet ID, Inc, founder and former director of Yale University’s Yale-Griffin Prevention Research Center and past president of the American College of Lifestyle Medicine, to its Scientific Advisory Board (SAB). Dr. Katz is a leading expert in nutrition, health promotion and the prevention of chronic disease through his work as a researcher, author and clinician.
Feb 24, 2021 06:30 am ET
New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients
ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19” were published Feb. 20 on medRxiv, a preprint publication website. The Phase 3 study demonstrated that patients with mild-to-moderate COVID-19 receiving standard of car
Feb 22, 2021 06:30 am ET
ChromaDex Announces $25 Million Private Placement of Common Stock
ChromaDex Corp. (NASDAQ: CDXC) announced today that it has entered into a securities purchase agreement for the sale of $25.0 million of its common stock in a private placement. The private placement was led by a new international investor and is expected to close on or about February 23, 2021, subject to the satisfaction of customary closing conditions. In connection with the investment, the Company agreed to sell 3,846,153 shares of its common stock at a per share price of $6.50, for gross proceeds of approximately $25.0 million.
Feb 19, 2021 06:35 am ET
ChromaDex to Report Fourth Quarter 2020 Financial Results on Wednesday, March 10, 2021
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., March 10, 2021 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended December 31, 2020. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
Feb 04, 2021 06:35 am ET
New Study Results Finds Nutritional Protocol Including Nicotinamide Riboside Reduces Liver Fat and Improves Liver Function
ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Cofactor Supplementation Reduces Liver Fat in Nonalcoholic Fatty Liver Disease” were published on Cell Press Sneak Peek, a preprint publication website for papers under review by Cell Press Journals. The Phase 2 study rep
Dec 02, 2020 06:35 am ET
ChromaDex to Present at Benzinga’s Inaugural Small Cap Conference in December 2020
ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the December 2020 Benzinga Small Cap Conference on Wednesday, December 9, 2020 at 11:15am ET (8:15am PT). This inaugural Small Cap Conference is a day dedicated to bridging the gap between Small Cap companies, investors and traders. The event will have multiple days of networking and education in a virtual setting.
Nov 17, 2020 06:35 am ET
ChromaDex Announces New Clinical Trial to Investigate Niagen® and Milk Production Among Mothers in the Neonatal Intensive Care Unit (NICU)
ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a human clinical trial of Niagen® (nicotinamide riboside, or NR) investigating its potential to increase milk production among preterm mothers. This new human trial follows promising preclinical results which showed NR supplementation benefited bot
Nov 09, 2020 06:32 am ET
ChromaDex and Watsons Launch New TRU NIAGEN® EX Stick Packs in Hong Kong, Expanding Product Line and Advancing Global Retail Partnership
ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive launch of its TRU NIAGEN® EX Stick Packs with Watsons Hong Kong, available online and in all Watsons Hong Kong stores. TRU NIAGEN® has been the #1 selling supplement in Watsons Hong Kong, and TRU NIAGEN® EX offers an alternative delivery method for the well-studied healthy aging vitamin, available to mix with one’s favorite beverage or sports drink.
Nov 04, 2020 04:01 pm ET
ChromaDex Corporation Reports Third Quarter 2020 Financial Results
ChromaDex Corp. (Nasdaq:CDXC) today reported third quarter financial results.
Oct 28, 2020 06:35 am ET
ChromaDex to Report Third Quarter 2020 Financial Results on Wednesday, November 4, 2020
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., November 4, 2020 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2020. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
Oct 19, 2020 06:32 am ET
New Study from NIH Finds Nicotinamide Riboside Helps Improve Telomere Dysfunction in Human Cells, Mice
ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study published in The European Molecular Biology Organization Journal looking at the effect of nicotinamide riboside (NR) on maintaining telomeres, the protective regions at the end of DNA strands. Th
Oct 14, 2020 09:10 am ET
Celltrient™ Cellular Energy Products Featuring Tru Niagen® Launch in US
ChromaDex Corp. (NASDAQ:CDXC) today announced its flagship ingredient, Tru Niagen®, is now available in Nestlé Health Science’s new Celltrient™ Cellular Energy, a protein-based flavored drink mix to help renew natural processes that decline as we age. The new product includes a 250mg serving of Tru Niagen® (nicotinamide riboside, or NR) and is one of three products under the new Celltrient brand.
Oct 08, 2020 06:32 am ET
New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function
ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study from Nature Immunology that found nicotinamide riboside (NR) helped energize tumor infiltrating T-cells (TILs) in samples extracted from mice. In a preclinical mouse model, NR was shown to improve T-cell function, which is a com
Oct 06, 2020 06:35 am ET
ChromaDex Announces Study Results Showing Nutritional Protocol Including Nicotinamide Riboside Plus Standard of Care Reduces Recovery Time in COVID-19 Patients by Nearly 30%
ChromaDex Corp. (NASDAQ:CDXC) today announced that results from the study “Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19” were published on the open access preprint publication server medRxiv.org. The Phase 2 study reported patients with mild-to-moderate COVID-19 expe
Sep 09, 2020 06:33 am ET
New Preclinical Study Finds Niagen® Prevents Light-Induced Retinal Damage in Mice
ChromaDex Corp. (NASDAQ:CDXC) today announced new preclinical research published in Investigative Ophthalmology & Vi
Aug 31, 2020 05:00 pm ET
LD Micro 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 27, 2020 03:35 pm ET
9th Annual Gateway Conference to Virtually Showcase Leading Companies on September 9-10, 2020
Executives from a Range of Industries to Present to 500+ Institutional Investors & Analysts
Aug 26, 2020 06:32 am ET
ChromaDex to Present at the LD 500 Virtual Investor Conference
ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at the LD 500 investor conference. The LD 500 will take place on September 1st through the 4th.
Aug 18, 2020 06:32 am ET
New Pilot Study Indicates Niagen® May Reduce Inflammatory Cytokines in Stage D Heart Failure Patients
ChromaDex Corp. (NASDAQ:CDXC) today announced the 11th published human trial on its patented NAD-boosting nutrient Niagen®, further highlighting its potential to support cardiovascular health in humans. A NIH funded study by Cardiology Division and Mitochondria & Metabolism Center at the University of Washington, published in
Aug 06, 2020 04:01 pm ET
ChromaDex Corporation Reports Second Quarter 2020 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today reported second quarter 2020 financial results.
Aug 05, 2020 09:00 am ET
LD Micro - Announces Preliminary List of Presenters for the LD-500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Jul 28, 2020 06:32 am ET
ChromaDex to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., August 6, 2020 at 4:30 p.m. ET to discuss its financial results for the second quarter ended Jun. 30, 2020. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
Jul 16, 2020 06:33 am ET
New Preclinical Study Finds Niagen® Corrects Social Deficits in Mouse Model of Autism
ChromaDex Corp. (NASDAQ:CDXC) today announced the results of a new preclinical study published in Nature Scientific Reports investigating the role of Niagen® (patented nicotinamide riboside) in addressing social deficits in Autism Spectrum Disorder (ASD). This new study joins a growing body of
Jul 14, 2020 06:32 am ET
ChromaDex External Research Program (CERP™) Achieves 200th Material Transfer Agreement for Niagen® (Nicotinamide Riboside) Research
ChromaDex Corp. (NASDAQ:CDXC) today announced the Company has signed its 200th material transfer agreement (MTA) through its global ChromaDex External Research Program (CERP™). The program provides Niagen® (nicotinamide riboside) ingredient and placebos at no cost as well as technical expertise and intellectual property support to leading research institutions and universities around the world, advancing the evidence and understanding of the health impact of increasing NAD+ levels through NR supplementation. The program has resulted in 60 publications to date, including 1
Jul 09, 2020 06:36 am ET
ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model
ChromaDex Corp. (NASDAQ:CDXC) today announced the latest preclinical findings indicating Niagen® (patented nicotinamide riboside) inhibits replication of a form of Coronavirus, the virus that causes COVID-19 infection, in mouse cells.
Jul 07, 2020 06:34 am ET
ChromaDex and the NIH-NIAID Rocky Mountain Laboratories Announce Study to Assess the Therapeutic Potential of Niagen® in COVID-19 Animal Models
ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a preclinical study in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). This study will assess if administration of Niagen® (nicotinamide riboside, or NR) can reduce viral burden and inflammation in mouse and hamster models of COVID-19. ChromaDex’s patent-protected NR is a unique nutrient that supports cellular energy production and healthy mitochondrial function through efficient restoration of NAD+ levels. The study
Jun 30, 2020 06:32 am ET
New Preclinical Findings Suggest Boosting NAD+ with Niagen® Holds Potential for Slowing Aging Process and Reducing Metabolic Damage
ChromaDex Corp. (NASDAQ:CDXC) today announced the results of multiple new preclinical studies that illustrate the multifaceted potential of Niagen® (nicotinamide riboside or NR) in bolstering cellular health to counteract or reduce progression of numerous degenerative conditions. The proven ability of Niagen® to raise NAD+ levels was found to contribute to positive effects in preclinical models of aging, fertility, and circadian rhythms, and in a clinical study on liver function. Several of these studies were made possible through the global
Jun 17, 2020 06:33 am ET
ChromaDex Research & Development Facility Earns ISO/IEC 17025:2017 Accreditation
ChromaDex Corp. (NASDAQ:CDXC) announced today it has achieved ISO/IEC 17025:2017 quality standard for laboratory testing, the world’s most respected quality management standard. This accreditation covers testing of the Company’s Tru Niagen® consumer products, its Niagen® ingredient, and phytochemical reference standards performed out of its quality control and R&D facility in Longmont, Colorado. The accreditation requires demonstration of full and continuous compliance with the most rigorous ISO quality standards, enabling ChromaDex to test and analyze its Tru Niagen® product, ingredients, and
Jun 16, 2020 06:32 am ET
ChromaDex to Present at June 2020 Lytham Partners Virtual Investor Growth Conference
ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 2:00pm ET (11:00am PT).
Jun 03, 2020 06:33 am ET
First-of-Its-Kind Human Tissue Study Finds Link Between NAD Decline and Alcohol-Related Liver Disease (ArLD)
ChromaDex Corp. (NASDAQ: CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced today the publication of a study evaluating the NAD metabolome in human liver samples from people with liver diseases including alcohol-related liver disease (ArLD). The study, published in
Jun 01, 2020 06:32 am ET
ChromaDex to Host Symposium on NAD+ in Human Health and Disease at NUTRITION 2020 LIVE ONLINE Annual Meeting
ChromaDex Corp. (NASDAQ:CDXC) announced today it has organized a virtual symposium entitled “Nicotinamide Adenine Dinucleotide (NAD+) in Human Health and Disease: The State of the Science on Nutrition Interventions” tomorrow Tuesday, June 2, from 8:30 to 10:00 AM EDT at NUTRITION 2020 LIVE ONLINE, the annual meeting hosted
May 27, 2020 06:32 am ET
ChromaDex to Participate in Panel on Master Files for Dietary Supplements Hosted by the American Conference Institute (ACI) and Council for Responsible Nutrition (CRN)
ChromaDex Corp. (NASDAQ:CDXC) today announced its participation in a panel discussion titled “What New Dietary Ingredient Master Files Mean for Innovation & Compliance,” hosted by the American Conference Institute (ACI) and Council for Responsible Nutrition (CRN). As the global leader in NAD+ science, ChromaDex maintains three New Dietary Ingredient (NDI) notifications from the Food & Drug Administration (FDA) for its proprietary Niagen® (nicotinamide riboside) ingredient and has obtained further regulatory approval in Canada, the European Union, and Australia.
May 21, 2020 06:32 am ET
ChromaDex Chief Scientific Advisor Dr. Charles Brenner Receives 2020 National Scientific Achievement Award from the American Society for Nutrition
ChromaDex Corp. (NASDAQ:CDXC) today announced Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa and ChromaDex Chief Scientific Advisor, was named the 2020 recipient of the Mary Swartz Rose Senior Investigator Award from the American Society for Nutrition (ASN) and its Foundation. This award, presented by ASN and supported by the Council for Responsible Nutrition (CRN), recognizes an investigator who has contributed outstanding research in the field of bioactive compounds for human health.
May 11, 2020 04:01 pm ET
ChromaDex Corporation Reports First Quarter 2020 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2020 financial results.
May 06, 2020 06:32 am ET
Ninth Published Human Trial on Niagen® Nicotinamide Riboside (NR) Shows Increase in NAD+ Levels, Additional Research Highlights Downfalls of Nicotinamide Mononucleotide (NMN)
ChromaDex Corp. (NASDAQ:CDXC) today announced the results of several new studies, which have uncovered new clinical and preclinical findings for its Niagen® (nicotinamide riboside, or NR) cellular nutrient, paving the way for continued research. Through its industry leading research program, called the ChromaDex External Research Program (CERP), ChromaDex provides its patented nicotinamide riboside (NR, or Niagen) ingredient to research institutions and universities at no cost. ChromaDex continues to support NAD+ research and through CERP has developed a global community of esteemed
May 01, 2020 06:32 am ET
ChromaDex to Report First Quarter 2020 Financial Results on Monday, May 11, 2020
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Mon., May 11, 2020 at 4:30 p.m. ET to discuss its financial results for the first quarter ended Mar. 31, 2020. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
Apr 28, 2020 06:33 am ET
Cellular Health Market Leader Tru Niagen® to Launch in U.K. Online and in Retail Stores Exclusively with Superdrug, Expanding Global Retail Partnership Between ChromaDex and A.S. Watson Group
ChromaDex Corp. (NASDAQ:CDXC) announced today the expansion of its partnership with A.S. Watson Group into Europe and launch of its flagship Tru Niagen® cellular health product online and in over 200 Superdrug stores across the Unit
Apr 23, 2020 06:32 am ET
ChromaDex and Watsons Launch New Tru Niagen® Beauty Cellular Nutrient in Hong Kong, Broadening Global Retail Partnership
ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive launch of its new Tru Niagen® Beauty cellular health and beauty daily supplement with Watsons Hong Kong, available online and in all Watsons stores in Hong Kong.
Apr 20, 2020 06:32 am ET
ChromaDex Commits to COVID-19 Research Following Promising Initial Preclinical Findings Showing Viral Infections Deplete NAD and SARS-CoV-2-Infected Cells Activate NAD Defense Pathway That Utilizes Ni
ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on nicotinamide adenine dinucleotide (NAD) and innovators behind Niagen® (patented nicotinamide riboside) science, announced today the publication of results from preclinical research on cells and animal tissue infected with Coronavirus and a COVID-19 cadaver in the online scientific publishing website
Apr 14, 2020 06:32 am ET
Mar 23, 2020 06:30 am ET
Cellular Health Market Leader Tru Niagen® Launches Online in Australia
ChromaDex Corp. (NASDAQ:CDXC) announced today the e-commerce launch of Tru Niagen® in Australia with distribution partner Matakana Health Limited (MHL). Tru Niagen received its listing number on the Australian Registry of Therapeutic Goods (ARTG)...
Mar 12, 2020 04:44 pm ET
ChromaDex Corrects Statements Made by an Unaffiliated Third Party Regarding its Product and COVID-19
ChromaDex Corp. (NASDAQ:CDXC) seeks to correct statements made by an unaffiliated third-party, Merkel Media Group on behalf of its unnamed client, implying unsupported health claims about Tru Niagen and COVID-19. There are no published human...
Mar 10, 2020 04:01 pm ET
CHROMADEX CORPORATION REPORTS 2019 FINANCIAL RESULTS
ChromaDex Corp. (NASDAQ:CDXC) today reported fourth quarter 2019 financial results. “We delivered strong performance across key metrics in 2019, secured regulatory approval in the EU and Australia, and published the sixth human clinical...
Feb 27, 2020 06:30 am ET
New Niagen® Nicotinamide Riboside (NR) Study Deepens Understanding of NAD Decline and Hearing Loss in Animal Model
ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced today the publication of a preclinical study in the journal Aging and Mechanisms of Disease,...
Feb 25, 2020 06:30 am ET
ChromaDex to Report Fourth Quarter 2019 Financial Results on Tuesday, March 10, 2020
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., Mar. 10, 2020 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended Dec. 31, 2019. The financial results will be reported in a press...
Feb 12, 2020 06:30 am ET
ChromaDex Partners with Personalized Nutrition Company, Persona Nutrition, Expanding Global Partnership with Nestlé Health Science
ChromaDex Corp. (NASDAQ:CDXC) today announced the launch of its flagship cellular health supplement Tru Niagen® (nicotinamide riboside) as a supplement offering in Nestlé Health Science’s (NHSc) personalized nutrition service – Persona Nutrition....
Feb 03, 2020 06:30 am ET
ChromaDex Launches New Line of High Purity Cannabinoid (CBD) Reference Standards Available for Research and Analytical Testing Worldwide
ChromaDex Corp. (NASDAQ:CDXC) today announced the expansion of its industry-leading reference standards business with a new line of cannabinoid (CBD) reference standards available to researchers across the globe.  These new materials are for...
Jan 15, 2020 06:30 am ET
ChromaDex Achieves New Regulatory Milestones in the European Union & Australia
ChromaDex Corp. (NASDAQ:CDXC) today announced regulatory authorizations to sell its patented nicotinamide riboside chloride (NR, or Niagen®) to consumers in both the European Union and in Australia. ChromaDex received its listing number for Tru...
Jan 06, 2020 06:30 am ET
First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension
ChromaDex Corp. (NASDAQ:CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced today the initiation of a first-of-its-kind Phase 1 clinical study sponsored by the...
Dec 16, 2019 06:30 am ET
ChromaDex Wins Nutritional Outlook’s 2019 “Best of Industry” Ingredient Supplier Award for Niagen®
ChromaDex Corp. (NASDAQ:CDXC) announced today that Nutritional Outlook®, a leading publication for the nutraceuticals industry, recently awarded ChromaDex the 2019 “Best of Industry Award,” in the “Ingredient Supplier” category, for Niagen®...
Dec 11, 2019 06:30 am ET
ChromaDex Launches Tru Niagen® Pro 500, the Largest Serving of Patented Nicotinamide Riboside Available Worldwide
ChromaDex Corp. (NASDAQ:CDXC) today announced the launch of Tru Niagen® Pro 500, the largest daily serving of its patented nicotinamide riboside (NR, or Niagen®) ingredient in the world.  The product will be available exclusively through licensed...
Dec 05, 2019 06:30 am ET
ChromaDex and Matakana Announce Expanded Retail Partnership in Australia & New Zealand
ChromaDex Corp. (NASDAQ:CDXC) announced today the expansion of its partnership with Matakana Health (MHL) until early 2023, which will now include Australia in its territory.  On Monday, ChromaDex announced the receipt of approval of nicotinamide...
Dec 02, 2019 06:30 am ET
ChromaDex Receives Approval for Nicotinamide Riboside Chloride as an Ingredient for Complementary Medicines from the Australian Therapeutic Goods Administration (TGA)
ChromaDex Corp. (NASDAQ:CDXC) today announced that it has received approval from the Australian Therapeutic Goods Administration (TGA) for its patented nicotinamide riboside chloride (NR) for use in listed complementary medicines.  The listing...
Nov 20, 2019 06:30 am ET
European Commission Votes in Favor on Nicotinamide Riboside Chloride as a Novel Food
ChromaDex Corp. (NASDAQ:CDXC) today announced that European Member States have voted in favor of listing Nicotinamide Riboside Chloride (NR) as a novel food ingredient at a daily serving of 300mg for the healthy adult population. This approval...
Nov 12, 2019 04:01 pm ET
ChromaDex Corporation Reports Third Quarter 2019 Financial Results   
ChromaDex Corp. (NASDAQ:CDXC) today reported third quarter 2019 financial results. “We had another strong quarter with total net sales of $12.1 million, up 9% sequentially and 48% year-over-year,” said ChromaDex CEO Rob Fried. “In addition, we...
Nov 04, 2019 06:30 am ET
ChromaDex to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., Nov. 12, 2019 at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sept. 30, 2019. The financial results will be reported in a press...
Oct 31, 2019 06:30 am ET
Tru Niagen® Wins ‘Most Favourite Brand’ Award Among Watsons Hong Kong Loyalty Members
ChromaDex Corp. (NASDAQ:CDXC) announced today its Tru Niagen® product was recognized as “MoneyBack Members’ Most Favourite Brand” at the Health, Wellness & Beauty Awards 2019 held in Hong Kong on October 24. The breakthrough cellular health product...
Oct 17, 2019 06:30 am ET
New Study Demonstrates a Unique Role of Nicotinamide Riboside Over Other NAD Precursors
ChromaDex Corp. (NASDAQ:CDXC) announced today that the  results of a preclinical study conducted by Nestlé were published last month in the journal Nature Communications, a peer-reviewed open access scientific journal published by the Nature...
Oct 11, 2019 06:30 am ET
ChromaDex Statement Regarding the October 9th Order in the Central District of California Litigation
ChromaDex Corp. (NASDAQ:CDXC) issued the following statement. We would like to take this opportunity to comment on the latest order from the California court regarding the ongoing litigation with Elysium. This started as a breach of contract...
Oct 07, 2019 06:30 am ET
Humanitarian Grant Awarded for Preclinical Study on the Impact of NAD Precursor Vitamins on Milk Bioactive Production and Brain Development in Rodents
Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa, receives a research grant from the Bill & Melinda Gates Foundation to study the effects of NAD-boosting supplements on the production of bioactive...
Sep 26, 2019 06:30 am ET
ChromaDex to Present at the 5th Annual B. Riley FBR Consumer and Media Conference
ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 5th Annual B. Riley FBR Consumer and Media Conference at the Sofitel Hotel in New York, NY....
Sep 10, 2019 08:00 am ET
Industry Leaders Aubrey De Grey And Frank Jaksch Join Yuva Biosciences Advisory Board
BIRMINGHAM, Ala., Sept. 10, 2019 /PRNewswire/ -- Yuva Biosciences, Inc., an anti-aging company developing cosmeceuticals as well as pharmaceuticals targeted at aging-associated hair loss, wrinkled skin, and reduced energy, today announced that Aubrey de Grey, Ph.D. and Frank L. Jaksch, Jr. have joined the Company's Advisory Board.
Aug 14, 2019 09:10 am ET
ChromaDex Announces $7 Million Private Placement of Common Stock
ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a securities purchase agreement for the sale of $7.0 million of its common stock in a private placement. The private placement was led by new strategic investors. The private...
Aug 07, 2019 04:10 pm ET
ChromaDex Receives Positive Opinion on Nicotinamide Riboside as a Novel Food from the World-Leading European Food Safety Authority (EFSA)
ChromaDex Corp. (NASDAQ:CDXC) today announced that the European Food Safety Authority (EFSA) has issued a positive opinion on Nicotinamide Riboside (NR) as a novel food ingredient for use in a food supplement at a daily serving of 300mg for the...
Aug 07, 2019 04:01 pm ET
ChromaDex Corporation Reports Second Quarter 2019 Financial Results   
ChromaDex Corp. (NASDAQ:CDXC) today reported second quarter 2019 financial results. “We successfully continue to build our global TRU NIAGEN brand and consequentially had another quarter strengthening our business momentum, economics...
Aug 06, 2019 04:05 pm ET
ChromaDex Adds Top Talent to its Leadership Team
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today three strategic hires to its executive team. Joining the company are Megan Jordan as Chief Communications...
Jul 31, 2019 04:05 pm ET
ChromaDex to Report Second Quarter 2019 Financial Results on Wednesday, August 7, 2019
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., August 7, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the second quarter ended June 30, 2019. The financial results will be reported in a...
Jul 24, 2019 06:30 am ET
TRU NIAGEN® Expands Canadian Retail Footprint with Distribution at Whole Foods Ontario Locations
ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product, Tru Niagen® (nicotinamide riboside) is now available in all seven Whole Foods Market locations across Ontario, in addition to select Pure Pharmacy locations, Fullscript...
Jul 23, 2019 06:30 am ET
ChromaDex Appoints Scripps Research Professor of Molecular Medicine, Brunie H. Felding, PhD, to the Scientific Advisory Board
ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed Brunie H. Felding, Ph.D., Associate Professor, Department of Molecular Medicine, Scripps Research Institute, California Campus, to the Scientific Advisory Board (SAB). ChromaDex CEO...
Jul 08, 2019 06:30 am ET
Newly Published Nicotinamide Riboside Study Further Demonstrates Safety of Sustained Niagen Supplementation and Optimal Dosing Levels
ChromaDex Corp. (NASDAQ:CDXC) announced today that the results of its latest clinical study were published Friday in the journal Scientific Reports. The largest trial of nicotinamide riboside (NR) published to date, the new study further validates...
Jun 05, 2019 06:30 am ET
TRU NIAGEN® Awarded ‘Ingredient of the Year: Healthy Aging’ by NutraIngredients-USA
ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product, Tru Niagen® (nicotinamide riboside) received the ‘Ingredient of the Year: Healthy Aging’ award at the NutraIngredients-USA Awards in New Orleans on June 3, 2019. “We are...
May 15, 2019 04:01 pm ET
ChromaDex to Present at the 20th Annual B. Riley FBR Investor Conference
ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 20th Annual B. Riley FBR Investor Conference at the Beverly Hilton Hotel in Beverly Hills, CA....
May 09, 2019 04:01 pm ET
ChromaDex Corporation Reports First Quarter 2019 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2019 financial results. “Nutritional interventions that support cellular health, including boosting NAD levels with our product TRU NIAGEN®, are some of the most actionable steps consumers...
May 09, 2019 08:20 am ET
ChromaDex Announces $10 Million Issuance of Convertible Notes
ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible notes in a private placement.  The transaction was led by international strategic investors. The...
May 02, 2019 06:30 am ET
ChromaDex to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 9, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2019. The financial results will be reported in a...
Apr 24, 2019 06:30 am ET
ChromaDex Furthers TRU NIAGEN® Global Expansion in Canada with WELL Health Technologies
ChromaDex Corp. (NASDAQ:CDXC) announced today a new distribution partnership for TRU NIAGEN® with Vancouver-based WELL Health Technologies Corp. (TSX.V: WELL) who intends on distributing TRU NIAGEN® via its partner network of pharmacy and other...
Apr 15, 2019 06:30 am ET
ChromaDex Drives Global Expansion Strategy for TRU NIAGEN® with Specialty Retail Launch and Expanded eCommerce Distribution in Canada
ChromaDex Corp. (NASDAQ:CDXC) announced today the latest milestone in its global expansion strategy for TRU NIAGEN®, with a strategic deal with specialty retailer Showcase in Toronto, Canada. Tru Niagen is now available in 36 Showcase stores in the...
Apr 09, 2019 06:30 am ET
New Study Deepens Research Into the Potential Cardiovascular Health Benefits of Supplementation with Nicotinamide Riboside (NR)
ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a new preclinical study showed that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen®) helps maintain heart function in mice by stimulating a conserved cellular response called the “mitochondrial unfolded protein response” (UPRmt
Apr 09, 2019 06:30 am ET
New Study Deepens Research Into the Potential Cardiovascular Health Benefits of Supplementation with Nicotinamide Riboside (NR)
ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a new preclinical study showed that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen®) helps maintain heart function in mice by stimulating a conserved...
Apr 03, 2019 06:30 am ET
Dr. Charles Brenner, Discoverer of Nutrient Nicotinamide Riboside as a Vitamin, Announced as Speaker at Upgrade XP’s Sixth Annual Biohacking Conference
ChromaDex Corp. (NASDAQ:CDXC) announced today its Chief Scientific Advisor, Dr. Charles Brenner, the world’s foremost authority on NAD metabolism and discoverer of nicotinamide riboside as a vitamin, will speak at the Sixth Annual Biohacking...
Apr 01, 2019 08:40 am ET
Consolidated Research: 2019 Summary Expectations for Vishay Intertechnology, Belmond, Silicon Motion Technology, Ardmore Shipping, Northwest Pipe, and ChromaDex — Fundamental Analysis, Key Performance
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Vishay Intertechnology, Inc. (NYSE:VSH), Belmond Ltd. (NYSE:BEL), Silicon...
Mar 11, 2019 04:01 pm ET
ChromaDex to Present at the 31st Annual ROTH Conference
ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, Chairman and Co-Founder, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 31st annual ROTH Capital Partners Conference at the...
Mar 08, 2019 06:30 am ET
ChromaDex Brings TRU NIAGEN® to SXSW® 2019
ChromaDex Corp. (NASDAQ:CDXC) announced today it will feature its cellular health product, TRU NIAGEN®, at SXSW®, as it marks the achievement of attaining over 160 research collaborations around the world on its patented NIAGEN® (nicotinamide...
Mar 07, 2019 04:01 pm ET
ChromaDex Corporation Reports 2018 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today reported fourth quarter and full year 2018 financial results. “Our momentum continues with another strong quarter, and a strong year overall.  In 2018, we successfully focused on the fundamentals, continuing...
Mar 01, 2019 06:30 am ET
ChromaDex to Present at the 39th Annual Cowen Health Care Conference
ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 39th Annual Cowen Heath Care Conference at the Boston Marriott Copley Place in Boston, MA....
Feb 28, 2019 06:30 am ET
ChromaDex to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., Mar. 7, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the fourth quarter ended December 31, 2018. The financial results will be reported in...
Jan 23, 2019 06:30 am ET
New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model
ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a first-of-a-kind preclinical study on lactation have shown that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen) confers significant and enduring physiological benefits to mothers and offspring. Conducted at the University of Iowa by Principal Investigator Dr. Charles Brenner, the Roy J. Carver Chair & Head of Biochemistry at the University of Iowa, as well as a founding co-director of the University of Iowa Obesity Initiative and Chief Scientifi
Jan 23, 2019 06:30 am ET
New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model
ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a first-of-a-kind preclinical study on lactation have shown that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen) confers significant and enduring...
Jan 22, 2019 04:05 pm ET
ChromaDex Prepared to Proceed with Patent Infringement Action Against Elysium Health
ChromaDex Corp. (NASDAQ:CDXC) today reported the rejection of Elysium Health Inc.’s challenge to Claim 2 of U.S. Patent No. 8,383,086 ("the '086 patent") by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office....
Dec 20, 2018 04:05 pm ET
ChromaDex Corp. and Nestlé Health Science Enter Global Commercial License and Supply Agreement for TRU NIAGEN®
ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a license and supply agreement with Nestlé Health Science (NHSc), a global leader pioneering quality science-based nutritional health solutions. The agreement provides NHSc the exclusive...
Dec 17, 2018 06:30 am ET
TRU NIAGEN® Expands North American Footprint with Product Launch in Canada
ChromaDex Corp. (NASDAQ:CDXC) announced today it has officially launched TRU NIAGEN® in Canada, having received regulatory approval for sale by Health Canada. Directly from the innovators behind NIAGEN® (nicotinamide riboside), the product is now...
Dec 12, 2018 08:00 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Procter & Gamble, Qorvo, McDermott International, Chanticleer, ChromaDex, and Taubman Centers — New Research Emphasizes Economic Gro
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Procter & Gamble Company (NYSE:PG), Qorvo, Inc. (NASDAQ:QRVO),...
Dec 12, 2018 06:30 am ET
TRU NIAGEN® to be Featured at the American Academy of Anti-Aging Medicine Annual Meeting
ChromaDex Corp. (NASDAQ:CDXC) announced today it will feature TRU NIAGEN® (Booth #6095) at the American Academy of Anti-Aging Medicine World Congress, a gathering of physicians, researchers, and healthcare practitioners from Dec. 13-15 in Las...
Nov 28, 2018 08:35 am ET
Research Report Identifies OraSure Technologies, Sierra Wireless, Seres Therapeutics, Lydall, ChromaDex, and Capricor Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Move
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of OraSure Technologies, Inc. (NASDAQ:OSUR), Sierra Wireless, Inc....
Nov 28, 2018 06:30 am ET
ChromaDex to Present at the 11th Annual LD Micro Main Event
ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, Co-Founder & Executive Chairman, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 11th annual LD Micro Main Event at the Luxe...
Nov 20, 2018 06:30 am ET
New TRU NIAGEN® Stick Packs Target New Audiences and Consumer Needs
ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of TRU NIAGEN stick packs, offering a new delivery method of its revolutionary nicotinamide riboside ingredient to promote cellular energy and repair. The stick packs, which each provide...
Nov 07, 2018 04:01 pm ET
ChromaDex Corporation Reports Third Quarter 2018 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today reported third quarter 2018 financial results. “I’m encouraged by the progress we made in the third quarter and remain enthusiastic about the future, TRU NIAGEN continued to show dramatic growth and we are...
Nov 06, 2018 06:30 am ET
ChromaDex Appoints Matthew Roberts as Chief Scientific Officer and Senior Vice President of Innovation
ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Matthew Roberts as Chief Scientific Officer and Senior Vice President of Innovation, effective immediately. Roberts brings over 30 years of experience in scientific innovation and...
Oct 31, 2018 04:05 pm ET
ChromaDex to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., Nov. 7, 2018 at 4:30 p.m. Eastern time to discuss its financial results for the third quarter ended September 30, 2018. The financial results will be reported in a...
Oct 30, 2018 06:30 am ET
TRU NIAGEN® Recognized as Best Product & Most Popular Brand at Health, Wellness & Beauty Awards 2018 of Watsons Hong Kong
ChromaDex Corp. (NASDAQ:CDXC) announced today its TRU NIAGEN® product was recognized as “The Best Scientific Innovative Anti-Aging Health Supplement” at Health, Wellness & Beauty Awards 2018 held by Watsons Hong Kong under A.S. Watson Group on...
Oct 25, 2018 06:30 am ET
 TRU NIAGEN® to be Featured at One-Day Medical School at Yale University School of Medicine
ChromaDex Corp. (NASDAQ:CDXC) announced today its TRU NIAGEN® (nicotinamide riboside) nutrient will be featured at the inaugural One-Day Medical School conference, hosted by The Department of Obstetrics, Gynecology and Reproductive Sciences at the...
Oct 24, 2018 06:30 am ET
TRU NIAGEN® Daily Serving Strengthened Under FDA’s NDI Notification
ChromaDex Corp. (NASDAQ:CDXC) announced today it has strengthened its flagship TRU NIAGEN® (nicotinamide riboside) nutrient to 150mg capsules, two per day. The more potent product will launch on truniagen.com, effective today. “We are pleased to...
Oct 22, 2018 06:30 am ET
Science Behind TRU NIAGEN® to be Featured at the World Mitochondria Society Meeting
ChromaDex Corp. (NASDAQ:CDXC) announced today that it will present the science behind TRU NIAGEN® (nicotinamide riboside) at the 9th World Congress on Targeting Mitochondria 2018 in Berlin, Germany, from Oct. 23-25. Frank Jaksch, ChromaDex...
Oct 18, 2018 07:55 am ET
Market Trends Toward New Normal in LSC Communications, Corindus Vascular Robotics, Sprouts Farmers Market, Luminex, ChromaDex, and CareDx — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LSC Communications (NYSE:LKSD), Corindus Vascular Robotics, Inc....
Oct 03, 2018 06:30 am ET
TRU NIAGEN® PRO to be Featured at the North American Menopause Society (NAMS) Annual Meeting
ChromaDex Corp. (NASDAQ:CDXC) announced today that it will highlight its new TRU NIAGEN® PRO product at the NAMS Annual Meeting 2018 in San Diego, CA, beginning today through Oct. 6. “Aging is so much more than skin deep—down to the cellular...
Oct 02, 2018 06:30 am ET
ChromaDex Appoints Yan Chu as Managing Director, Asia Pacific
ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Yan Chu as Managing Director, Asia Pacific, effective today. Based in Singapore, Chu will lead the TRU NIAGEN® business for the region. Chu is joining ChromaDex from Comvita, an...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.